Bristol-Myers Squibb (BMY)

The company’s portfolio includes established and newer therapies used in areas such as cancer, blood disorders, autoimmune conditions, and stroke prevention. Bristol Myers Squibb is particularly associated with immuno-oncology, where medicines designed to help the immune system recognise and attack tumours have become an important part of modern cancer treatment. It also has a long-standing role in cardiovascular care and maintains research programmes aimed at replacing revenue from maturing blockbuster drugs with new launches and pipeline candidates.

Bristol Myers Squibb operates in a highly regulated and research-intensive industry where patent protection, clinical trial success, pricing pressure, and regulatory approvals are central to performance. The United States is its most important market and accounts for a large share of sales, making US drug pricing policy, reimbursement decisions, and prescribing trends especially relevant for investors.

The company grows through internal research as well as acquisitions, partnerships, and licensing deals that broaden its pipeline. Its scale, specialist sales capabilities, and experience in complex therapeutic categories make it one of the major large-cap pharmaceutical companies, while its investment case is closely tied to the durability of existing drugs and the commercial uptake of newer medicines.